Novo Nordisk reported 12.85B in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Bausch Health Companies USD 764M 63M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
Merck USD 2.82B 53M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Novo Nordisk 12.85B 44M Jun/2025
Novo Nordisk DKK 12.89B 1.58B Mar/2025
Pacira USD 55.19M 20.88M Jun/2025
Sanofi EUR 2.99B 103M Jun/2025
Supernus Pharmaceuticals USD 37.65M 21.88M Jun/2025